跳至主要内容
临床试验/NCT06097767
NCT06097767进行中(未招募)早期 1 期

Evaluation of the Incidence of Necrotizing Enterocolitis in Preterm Infants With Respiratory Distress Syndrome Undergoing Caffeine Therapy

Al-Azhar University1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2023年10月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
进行中(未招募)
入组人数
50
试验地点
1
主要终点
decreasing NEC rates

研究概览

简要总结

It is a randomized, prospective study; it will be carried out in the NICU at Alzahraa University Hospital including 50 newborn babies diagnosed with respiratory distress syndrome.

The purpose of this study is to :

  1. Investigate the protective caffeine on necrotizing enterocolitis in respiratory distress syndrome preterm infants.
  2. Detect the impact of caffeine protocol treatment on the in-incidence of necrotizing enterocolitis in respiratory distress syndrome preterm infants in neonatal intensive care

1- Control group It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks.

2- Caffeine-treated group It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
32 Weeks 至 35 Weeks(Child)
性别
All
接受健康志愿者

入选标准

  • All preterm infants with respiratory distress syndrome.

排除标准

  • Preterm admitted to NICU for other reasons rather than respiratory distress
  • Major congenital anomalies
  • spontaneous intestinal perforation
  • Endocrinal Dysfunctions

研究组 & 干预措施

Control group

Other

It includes preterm infants with respiratory distress syndrome aged 32 weeks-35 weeks receives regular intervention for RDS

干预措施: Amikacin (Drug)

Caffeine-treated group

Active Comparator

It includes preterm infants with respiratory distress syndrome who received caffeine treatment as intravenous caffeinospire (Caffeine citrate) 60 mg / 3 ml (20 mg /ml) 3 ml vial for injection.

干预措施: Caffeine citrate (Drug)

结局指标

主要结局

decreasing NEC rates

时间窗: 1 year

decreasing NEC rates and stage ≥2 and death.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Gellan Alaa Mohamed Kamel Morsy

Lecturer of pharmacology and toxicology

Al-Azhar University

研究点 (1)

Loading locations...

相似试验

the Incidence of Necrotizing Enterocolitis in... | 临床试验